The effect of valsartan on oxidative stress in type 2 diabetic patients with hypertension: prospective, randomized, open label, active control, multi-center study
Not Applicable
Completed
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0001498
- Lead Sponsor
- Ajou University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Type 2 DM patients
systolic BP (SBP) 135 – 160 mmHg and/or diastolic BP (DBP) 85 – 100 mmHg,
30 - 80 years of age,
not taking antihypertensive drugs within 2 weeks prior to screening date
HbA1c =9.0%.
Exclusion Criteria
secondary hypertension, impaired hepatic function (defined by serum levels of either ALT or AST >2.5 times the upper limit of normal), renal impairment (serum creatinine >2.0 mg/dL)), or any other clinically relevant serious disease, including malignancy, serious infection, heart failure, myocardial infarction or stroke within 6 months prior to the screening date, or patients who were pregnant, breast-feeding, or planning to bear a child, or whose low-density lipoprotein cholesterol (LDL-C) >160 mg/dL
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method oxidative stress marker
- Secondary Outcome Measures
Name Time Method metabolic parameters